ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline, IlDong Pharmaceutical and Lunan Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineIlDong PharmaceuticalLunan Pharmaceutical Group
studies on the registry4,1985039
open to participants now136119
phase 3 studies under way78010
reach primary completion within a year6704
programswith a study of their own in two years88+17 named onlynone read20

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineIlDong PharmaceuticalLunan Pharmaceutical Group
Phase 1

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
–

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 1

  1. F182112phase 1
  2. LNF2007phase 1
  3. LNF2105phase 1
  4. Dronedaroneno phase
  5. Budesonideno phase

and 3 more — sign in to see them all

40%
Phase 2

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%
–

Lunan Pharmaceutical Group: 4 of its 20 programs at phase 2

  1. F182112+CD38phase 2
  2. mosapridephase 2
  3. Vonorasan fumarate injection1phase 2
  4. Vonorasan fumarate injection2phase 2
20%
Phase 3

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%
–

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 3

  1. rulonilimabphase 3
  2. Beclomethasonephase 3
  3. Cetirizinephase 3
  4. Diphenhydraminephase 3
  5. F027phase 3

and 3 more — sign in to see them all

40%
Approved, new studies

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%
–00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
IlDong Pharmaceutical0 readouts · 0 phase 3············
Lunan Pharmaceutical Group4 readouts · 1 phase 3·

Lunan Pharmaceutical Group, Dec ’26: 1 program whose next study reaches primary completion

  1. LNF2007phase 1 · Dec 0 · NCT06752447
·

Lunan Pharmaceutical Group, Feb ’27: 2 programs whose next study reaches primary completion

  1. Vonorasan fumarate injection1phase 2 · Feb 0 · NCT06783257
  2. Vonorasan fumarate injection2phase 2 · Feb 0 · NCT06783257
···

Lunan Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Isosorbidephase 3 · Jun 30 · NCT06765993
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

IlDong Pharmaceutical

No programs read for this company.

Lunan Pharmaceutical Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 14 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineIlDong PharmaceuticalLunan Pharmaceutical Group
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Lunan Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Asthma2 of 3 · compare here

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

–

Lunan Pharmaceutical Group in Asthma: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Asthma in search

Multiple Myeloma2 of 3 · compare here

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

–

Lunan Pharmaceutical Group in Multiple Myeloma: 3 programs

  1. F182112 single-agentphase 3
  2. F182112+CD38phase 2
  3. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Multiple Myeloma in search

Lupus Erythematosus, Systemic2 of 3 · compare here

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

–

Lunan Pharmaceutical Group in Lupus Erythematosus, Systemic: 1 program

  1. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Lupus Erythematosus, Systemic in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

–

Lunan Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Breast Neoplasms2 of 3 · compare here

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

–

Lunan Pharmaceutical Group in Breast Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Breast Neoplasms in search

Colorectal Neoplasms2 of 3 · compare here–

Lunan Pharmaceutical Group in Colorectal Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Colitis, Ulcerative2 of 3 · compare here

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

–

Lunan Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colitis, Ulcerative in search

Diabetes Mellitus, Type 22 of 3 · compare here

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

–

Lunan Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. F027phase 3
  2. Valsartanphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Pruritus2 of 3 · compare here

GlaxoSmithKline in Pruritus: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Pruritus in search

–
Small Cell Lung Carcinoma2 of 3 · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

–

Lunan Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Hepatocellular2 of 3 · compare here

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

–

Lunan Pharmaceutical Group in Carcinoma, Hepatocellular: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Hepatocellular in search

Show all 14

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetGlaxoSmithKlineIlDong PharmaceuticalLunan Pharmaceutical Group
PDCD1dostarlimabrule, ivonescimabrule–rulonilimabrule
A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 65 of 88 · IlDong Pharmaceutical 0 of 0 · Lunan Pharmaceutical Group 8 of 20 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).